Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Angela Y. Jia (principal investigator)
Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· Phase 2· NRG Oncology· Source
Contact: Pedro Barata (principal investigator)
Active, not recruiting
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152· Phase 2· NRG Oncology· Source
Active, not recruiting
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013· Phase 2· SWOG Cancer Research Network· Source
Contact: Ankit Mangla (principal investigator)
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04268550· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NCT03801876· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Jennifer Beeler
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· Phase 2· NRG Oncology· Source
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Active, not recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· Phase 2· NRG Oncology· Source
Active, not recruiting
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source